IL214822A - Annals 2 - {9,8,7,6,3,2- (hexahydro-4,1-dioxino [3,2- g] isoquinoline-8-carbonyl-amino} - propionic acid and its pharmaceutical preparations - Google Patents

Annals 2 - {9,8,7,6,3,2- (hexahydro-4,1-dioxino [3,2- g] isoquinoline-8-carbonyl-amino} - propionic acid and its pharmaceutical preparations

Info

Publication number
IL214822A
IL214822A IL214822A IL21482211A IL214822A IL 214822 A IL214822 A IL 214822A IL 214822 A IL214822 A IL 214822A IL 21482211 A IL21482211 A IL 21482211A IL 214822 A IL214822 A IL 214822A
Authority
IL
Israel
Prior art keywords
dioxino
isoquinolin
hexahydro
carbonyl
amino
Prior art date
Application number
IL214822A
Other languages
English (en)
Hebrew (he)
Other versions
IL214822A0 (en
Original Assignee
Vtv Therapeutics Llc
Transtech Pharma Llc
Vtvx Holdings I Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc, Transtech Pharma Llc, Vtvx Holdings I Llc filed Critical Vtv Therapeutics Llc
Publication of IL214822A0 publication Critical patent/IL214822A0/en
Publication of IL214822A publication Critical patent/IL214822A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Secondary Cells (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL214822A 2009-03-30 2011-08-25 Annals 2 - {9,8,7,6,3,2- (hexahydro-4,1-dioxino [3,2- g] isoquinoline-8-carbonyl-amino} - propionic acid and its pharmaceutical preparations IL214822A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16452309P 2009-03-30 2009-03-30
US30934810P 2010-03-01 2010-03-01
PCT/US2010/029172 WO2010114824A1 (en) 2009-03-30 2010-03-30 Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

Publications (2)

Publication Number Publication Date
IL214822A0 IL214822A0 (en) 2011-11-30
IL214822A true IL214822A (en) 2016-08-31

Family

ID=42828657

Family Applications (1)

Application Number Title Priority Date Filing Date
IL214822A IL214822A (en) 2009-03-30 2011-08-25 Annals 2 - {9,8,7,6,3,2- (hexahydro-4,1-dioxino [3,2- g] isoquinoline-8-carbonyl-amino} - propionic acid and its pharmaceutical preparations

Country Status (17)

Country Link
US (3) US8383644B2 (enExample)
EP (1) EP2413693B1 (enExample)
JP (1) JP5755217B2 (enExample)
KR (1) KR101732978B1 (enExample)
CN (1) CN102378574B (enExample)
AU (1) AU2010232750B2 (enExample)
BR (1) BRPI1013579A2 (enExample)
CA (1) CA2757084C (enExample)
DK (1) DK2413693T3 (enExample)
EA (1) EA023430B1 (enExample)
ES (1) ES2553645T3 (enExample)
IL (1) IL214822A (enExample)
MA (1) MA33219B1 (enExample)
MX (1) MX2011010347A (enExample)
SG (1) SG174205A1 (enExample)
TN (1) TN2011000437A1 (enExample)
WO (1) WO2010114824A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102378574B (zh) 2009-03-30 2013-11-20 转化技术制药公司 取代的偶氮蒽衍生物、药物组合物及其使用方法
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
US8822527B2 (en) 2011-10-17 2014-09-02 Biotheryx, Inc. Substituted biaryl alkyl amides
KR102165434B1 (ko) * 2013-01-17 2020-10-14 브이티브이 테라퓨틱스 엘엘씨 2형 당뇨병 및 다른 장애의 치료를 위한 glp1r 작용제 및 메트포민의 조합 및 이것들의 사용법
CN107072970B (zh) 2014-08-29 2021-05-25 得克萨斯州大学系统董事会 用于治疗癌症和其他增殖性疾病的新的辣椒平类似物
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
TW201925204A (zh) * 2017-11-22 2019-07-01 日商第一三共股份有限公司 稠合三環化合物
JP7461104B2 (ja) * 2017-11-29 2024-04-03 中外製薬株式会社 Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物
CA3090823A1 (en) * 2018-05-08 2019-11-14 Vtv Therapeutics Llc Therapeutic uses of glp1r agonists
US10934279B2 (en) 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
CA3140972C (en) 2019-05-20 2024-06-18 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
MX2022008938A (es) * 2020-01-20 2022-10-18 Crescenta Biosciences Nuevos compuestos moduladores del metabolismo celular y usos de los mismos.
WO2021196951A1 (zh) 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
CN115461344B (zh) * 2020-04-01 2024-01-12 杭州中美华东制药有限公司 一种glp-1受体激动剂的晶型a及其制备方法
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
TW202210461A (zh) 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種（ｓ）—２—胺基—３—（４—（２，３—二甲基吡啶—４—基）苯基）丙酸甲酯二酸鹽的製備方法
TW202206420A (zh) 2020-05-28 2022-02-16 美商維特衛治療有限責任公司 用於製備glp-1受體促效劑的中間體和方法
CN115697968B (zh) * 2020-05-28 2024-03-29 杭州中美华东制药有限公司 (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法
CN115667222B (zh) * 2020-05-28 2023-09-29 杭州中美华东制药有限公司 一种制备glp-1受体激动剂的方法
EP4159737A4 (en) * 2020-05-28 2024-10-09 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. METHOD FOR PREPARING A GLP-1 RECEPTOR AGONIST-FREE BASE
TW202206412A (zh) 2020-05-28 2022-02-16 美商維特衛治療有限責任公司 製備（ｓ）－２－胺基－３－（４－（２，３－二甲基吡啶－４－基）苯基）丙酸甲酯及其鹽酸鹽的方法
JP2023539584A (ja) 2020-09-01 2023-09-15 江蘇恒瑞医薬股▲ふん▼有限公司 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
US20230382921A1 (en) * 2020-09-21 2023-11-30 Vtv Therapeutics Llc Amorphous Form of Isoquinoline Derivative
US12454511B2 (en) 2020-10-08 2025-10-28 Eli Lilly And Company 6-methoxy-3,4-dihydro-1H-isoquinolin compounds
WO2022078152A1 (zh) 2020-10-12 2022-04-21 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
US20240246959A1 (en) 2020-11-27 2024-07-25 Shenzhen Salubris Pharmaceuticals Co., Ltd. Benzimidazole derivative and preparation method therefor and medical use thereof
US20240208952A1 (en) 2021-03-22 2024-06-27 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Thiophene glp-1 receptor agonist and use thereof
WO2022202864A1 (ja) 2021-03-24 2022-09-29 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
CN117500789A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法
WO2022262615A1 (zh) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
CN117098758A (zh) 2021-06-24 2023-11-21 杭州中美华东制药有限公司 Glp-1受体激动剂及其组合物和用途
WO2023029979A1 (zh) * 2021-09-03 2023-03-09 杭州中美华东制药有限公司 Glp-1受体激动剂中间体的制备方法
CN118948849A (zh) 2021-09-08 2024-11-15 盐野义制药株式会社 用于预防和治疗与抗肥胖作用有关的疾病的药物
CA3233453A1 (en) * 2021-09-28 2023-04-06 Meimei Chen Solid composition of glp-1 receptor agonist
JPWO2024063143A1 (enExample) 2022-09-22 2024-03-28
WO2025057134A2 (en) 2023-09-14 2025-03-20 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795265A (fr) * 1972-02-09 1973-08-09 Philips Nv Nouveaux derives de quinoleine a activite pharmacologique
EP0233728A1 (en) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. 1,4-Benzoxazine derivatives their production and use
US5756532A (en) 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
US6815451B2 (en) * 2001-03-27 2004-11-09 Actelion Pharmaceuticals Ltd. 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists
ES2278064T3 (es) * 2001-10-19 2007-08-01 Transtech Pharma Inc. Derivados de beta-carbolina como inhibidores de ptp.
EP1458382A1 (en) 2001-12-21 2004-09-22 Novo Nordisk A/S Amide derivatives as gk activators
CN100432056C (zh) * 2003-03-26 2008-11-12 埃科特莱茵药品有限公司 四氢异喹啉基乙酰胺衍生物作为阿立新受体拮抗剂的应用
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
RU2284325C2 (ru) 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
WO2008118935A1 (en) * 2007-03-26 2008-10-02 Neurogen Corporation Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-ones
WO2009111700A2 (en) * 2008-03-07 2009-09-11 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
US8718994B2 (en) 2008-04-09 2014-05-06 Transtech Pharma, Llc Ligands for the GLP-1 receptor and methods for discovery thereof
CN102378574B (zh) 2009-03-30 2013-11-20 转化技术制药公司 取代的偶氮蒽衍生物、药物组合物及其使用方法
US8501982B2 (en) 2010-06-09 2013-08-06 Receptos, Inc. GLP-1 receptor stabilizers and modulators

Also Published As

Publication number Publication date
US8383644B2 (en) 2013-02-26
KR101732978B1 (ko) 2017-05-08
CN102378574A (zh) 2012-03-14
US20150148539A1 (en) 2015-05-28
EA023430B1 (ru) 2016-06-30
US20110160198A1 (en) 2011-06-30
IL214822A0 (en) 2011-11-30
CA2757084A1 (en) 2010-10-07
MA33219B1 (fr) 2012-04-02
AU2010232750A1 (en) 2011-09-08
BRPI1013579A2 (pt) 2020-11-03
CA2757084C (en) 2017-08-29
EP2413693B1 (en) 2015-09-09
TN2011000437A1 (en) 2013-03-27
JP2012522060A (ja) 2012-09-20
WO2010114824A8 (en) 2011-10-06
CN102378574B (zh) 2013-11-20
SG174205A1 (en) 2011-10-28
EA201171197A1 (ru) 2012-04-30
JP5755217B2 (ja) 2015-07-29
ES2553645T3 (es) 2015-12-10
HK1164050A1 (en) 2012-09-21
DK2413693T3 (en) 2015-11-16
EA201171197A8 (ru) 2014-10-30
US9175003B2 (en) 2015-11-03
EP2413693A4 (en) 2012-08-22
EP2413693A1 (en) 2012-02-08
AU2010232750B2 (en) 2015-10-29
US20130096150A1 (en) 2013-04-18
MX2011010347A (es) 2011-11-29
KR20120006506A (ko) 2012-01-18
US8987295B2 (en) 2015-03-24
WO2010114824A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
IL214822A (en) Annals 2 - {9,8,7,6,3,2- (hexahydro-4,1-dioxino [3,2- g] isoquinoline-8-carbonyl-amino} - propionic acid and its pharmaceutical preparations
IL275854A (en) Pharmaceutical composition and its administration
IL216171A (en) Lipidic Compound, Method for Preparing the Compound, Pharmaceutical and Lipid Preparations Containing Their Composition and Uses
IL201581A0 (en) Pharmaceutical formulations containing lipoic acid derivatives
IL220432A (en) History of theo [b – 3,2] pyridinedione and pharmaceutical preparations containing them
IL208203A (en) Annotations of 3,2-Dihydro-Pyrido-4,1-Exazine and 3,2-Dihydro-4-Oxa-9,1-Diazapananthrene, Preparation Processes and Pharmaceutical Preparations
IL213993A (en) History of 4,3,2,1-tetrahydropyrido [3,2-b] pyrazine-2-one and pharmaceutical preparations containing them
SI2407475T1 (sl) Priprava sintetične žolčne kisline
IL201611A0 (en) Lipoic acid derivatives
IL192826A0 (en) Thiazole derivatives, their preparation and pharmaceutical compositions containing them
IL204706A0 (en) Matrix - type pharmaceutical solid preparation
IL209348A0 (en) Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin
PL2364084T3 (pl) Niskodawkowe kompozycje farmaceutyczne kwasu liponowego i sposoby
IL213570A (en) History 8 - Alkoxy - s - Triazolo [5,1 - a] pyridine and pharmaceutical preparations containing them
EG26786A (en) Fertilizers contain sulfur and process to manufacture
IL206594A (en) The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
IL195813A0 (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
ZA201106299B (en) Composition comprising caftaric acid and/or derivatives thereof
PL2036892T3 (pl) Pochodne 1,2,4,5-tetrahydro-3H-benzazepin, sposób ich wytwarzania i zawierające je kompozycje farmaceutyczne
IL218539A (en) Annotated 4,1-Androsteadian-3-Oxo-9,6-Dihlo-16-Isoxazolidine-17-Noble N-Converted
SI2448940T1 (sl) Derivati 6,7,8,9-tetrahidro-pirimido(1,2-a)pirimidin-4-ona, njihova priprava in njihova farmacevtska uporaba
PT2193795E (pt) Composição farmacêutica aquosa contendo latanoprost
IL219959A (en) 7 - [5,3-Hydroxy-2- (3-Hydroxy-5-Phenyl-Pent-1-Inyl) -Cyclopnital] - n-Ethyl-Hept-5-Inamide (Bimetoprost) in crystalline form II and its pharmaceutical preparations
ZA200900237B (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
IL214579A0 (en) Phenoxy acetic acid derivatives, their preparation and pharmaceutical composition containing them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed